Thursday, January 04, 2018 10:15 PM ET
CRISPR Therapeutics (CRSP) sees Significant Insider Selling Continuing
A significant insider sale of the shares of CRISPR Therapeutics was indicated in a form 4 document filed with the SEC today, showing — Kurt von Emster, Director — sold 37,754 shares in the company having a market value of approximately $1,010,123. There have been 4 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 1,175,128 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 1,212,882 shares and have averaged 242,576 shares per transaction over this time period.
The number of insider buy/sell trades at CRISPR Therapeutics is higher than the 190 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 157 buy/sell trades during this period for an average of 0.8 transactions per company. The number of shares per buy/sell trade for CRISPR Therapeutics insiders was also higher. Within the peer group there were 26,685,061 shares purchased and 11,230,698 shares sold with company insiders having bought 132,089 shares on average.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data used in creating and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.